Skip to main navigation
Skip to search
Skip to main content
Prinses Máxima Centrum Home
Nederlands
English
Search content at Prinses Máxima Centrum
Home
Profiles
Research Groups
Equipment
Research output
Prizes
Activities
Press/Media
Trial Watch: Peptide vaccines in cancer therapy
Fernando Aranda
, Erika Vacchelli
,
Alexander Eggermont
, Jerome Galon
, Catherine Sautès-Fridman
, Eric Tartour
, Laurence Zitvogel
, Guido Kroemer
, Lorenzo Galluzzi
Research output
:
Contribution to journal
›
Review article
›
peer-review
101
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Trial Watch: Peptide vaccines in cancer therapy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Adaptive Immune Response
25%
Anticancer Agents
50%
Anticancer Vaccines
100%
Antigen-specific Immunity
25%
Antineoplastic
25%
Biological Mechanisms
25%
Cancer Therapy
100%
Cell-based
25%
Clinical Potential
25%
Clinical Trials
25%
Component-based
25%
DNA Bases
25%
High Profile
25%
Immune Checkpoint
25%
Immune Response
25%
Immune System
25%
Immunogenic
25%
Immunological Tolerance
25%
Immunosuppressive Cytokines
25%
In Cancer
100%
Innate Immune Response
25%
Late Development
25%
Malignant Cells
25%
Neoplastic Lesions
25%
Oncogenesis
25%
Oncoimmunology
25%
Peptide Vaccine
100%
Profile Study
25%
Prophylactic Treatment
25%
Purified Peptide
25%
Receptor Agonist
25%
Receptor Inhibitors
25%
Toll-like
25%
Tumor
25%
Tumor Antigen
25%
Tumor Progression
25%
Medicine and Dentistry
Adaptive Immunity
66%
Adjuvant
33%
Anticarcinogen
100%
Cancer Therapy
100%
Carcinogenesis
33%
Clinical Trial
33%
Cytokine
33%
Immune Response
33%
Immune System
33%
Immunological Tolerance
33%
Immunosuppressive Drug
33%
Innate Immunity
33%
Peptide
66%
Peptide Vaccine
100%
Toll Like Receptor Agonist
33%
Toll Like Receptor Antagonist
33%
Tumor
33%
Tumor Antigen
33%
Tumor Progression
33%
Immunology and Microbiology
Adaptive Immune System
100%
Adjuvant
50%
Agonist
50%
Cytokine
50%
Immune Response
50%
Immune System
50%
Immune Tolerance
50%
Immunosuppressive Drug
50%
Innate Immune System
50%
Peptide Vaccine
100%
Peptides
100%
Toll-Like Receptor
50%
Tumor Antigen
50%
Pharmacology, Toxicology and Pharmaceutical Science
Adjuvant
33%
Anticarcinogen
100%
Carcinogenesis
33%
Clinical Trial
33%
Cytokine
33%
Immunosuppressive Agent
33%
Malignant Neoplasm
100%
Peptide
66%
Peptide Vaccine
100%
Toll Like Receptor Agonist
33%
Toll Like Receptor Antagonist
33%
Tumor Antigen
33%
Tumor Growth
33%